We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Centene's Q3 Earnings Escape Industry's Cost Headwinds?
Read MoreHide Full Article
Key Takeaways
Centene will report Q3 2025 results on Oct. 29, with an expected loss of $0.21 per share.
Revenues are projected to rise 13.3% year over year to $47.62 billion, driven by premium growth.
Higher medical costs and lower Medicaid memberships may pressure Centene's bottom line.
Healthcare plan provider Centene Corporation (CNC - Free Report) is set to report third-quarter 2025 results on Oct. 29, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at a loss of 21 cents per shareon revenues of $47.62 billion.
The third-quarter earnings estimate remained stable over the past 60 days. The bottom-line projection indicates a year-over-year plunge of 113%. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year growth of 13.3%.
Image Source: Zacks Investment Research
For 2025, the Zacks Consensus Estimate for Centene’s revenues is pegged at $190.45 billion, implying a rise of 16.8% year over year. The consensus mark for 2025 EPS is pegged at $1.69, implying a decrease of 76.4%, year over year.
Centenebeat the earnings estimates in three of the last four quarters and missed once, with the average surprise being negative 5.2%. This is depicted in the figure below.
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
CNC has an Earnings ESP of 0.00% and a Zacks Rank #5 (Strong Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping Centene’s Q3 Results?
The Zacks Consensus Estimate for the company’s total commercial memberships indicates a 26.6% year-over-year increase, whereas our model estimate predicts a 23.1% growth, primarily due to growth in the commercial marketplace. Both the consensus estimate and our model estimate for Medicare PDP memberships signal nearly 17% growth from the year-ago quarter.
The Zacks Consensus Estimate projects the company’s premium growth at about 19% year over year, in line with our model forecasts. This is likely to have supported top-line growth in the to-be-reported quarter.
However, the Zacks Consensus Estimate for total membership indicates a 2.2% year-over-year decline, due to decreases in Medicaid and Medicare memberships. Both the consensus estimate and our model estimate for the company’s total Medicaid memberships indicate a nearly 2% decline from a year ago.
The consensus estimate for service revenues indicates a 7.2% fall from the year-ago quarter’s $784 million. Also, the Zacks Consensus Estimate for the company’s investment and other income indicates an 11.7% year-over-year decline from $432 million.
Moreover, following the industry trend, CNC’s medical costs are expected to have remained elevated in the third quarter. The Zacks Consensus Estimate for the total health benefits ratio is pegged at 93%, up from 89.2% in the year-ago period, meaning a reduced portion of premiums remaining in hand after paying claims. Our model estimate for total operating expenses indicates more than a 15% increase in the third quarter. These are expected to have affected the bottom line, making an earnings beat uncertain.
Stocks That Warrant a Look
While an earnings beat looks uncertain for Centene, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
The Zacks Consensus Estimate for Select Medical’s bottom line for the to-be-reported quarter of 18 cents per share has witnessed one upward revision against no downward movement over the past month. The consensus mark for Select Medical’s revenues is pegged at $1.32 billion.
Erasca, Inc. (ERAS - Free Report) has an Earnings ESP of +5.66% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Erasca’s bottom line for the to-be-reported quarter remained stable over the past week. Erasca’s earnings beat estimates in three of the past four quarters and met once, with an average surprise of 13%.
Humana Inc. (HUM - Free Report) has an Earnings ESP of +4.29% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Humana’s bottom line for the to-be-reported quarter is pegged at $2.91 per share, which remained stable over the past week. Humana beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Can Centene's Q3 Earnings Escape Industry's Cost Headwinds?
Key Takeaways
Healthcare plan provider Centene Corporation (CNC - Free Report) is set to report third-quarter 2025 results on Oct. 29, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at a loss of 21 cents per shareon revenues of $47.62 billion.
The third-quarter earnings estimate remained stable over the past 60 days. The bottom-line projection indicates a year-over-year plunge of 113%. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year growth of 13.3%.
Image Source: Zacks Investment Research
For 2025, the Zacks Consensus Estimate for Centene’s revenues is pegged at $190.45 billion, implying a rise of 16.8% year over year. The consensus mark for 2025 EPS is pegged at $1.69, implying a decrease of 76.4%, year over year.
Centenebeat the earnings estimates in three of the last four quarters and missed once, with the average surprise being negative 5.2%. This is depicted in the figure below.
Centene Corporation Price and EPS Surprise
Centene Corporation price-eps-surprise | Centene Corporation Quote
Q3 Earnings Whispers for Centene
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
CNC has an Earnings ESP of 0.00% and a Zacks Rank #5 (Strong Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping Centene’s Q3 Results?
The Zacks Consensus Estimate for the company’s total commercial memberships indicates a 26.6% year-over-year increase, whereas our model estimate predicts a 23.1% growth, primarily due to growth in the commercial marketplace. Both the consensus estimate and our model estimate for Medicare PDP memberships signal nearly 17% growth from the year-ago quarter.
The Zacks Consensus Estimate projects the company’s premium growth at about 19% year over year, in line with our model forecasts. This is likely to have supported top-line growth in the to-be-reported quarter.
However, the Zacks Consensus Estimate for total membership indicates a 2.2% year-over-year decline, due to decreases in Medicaid and Medicare memberships. Both the consensus estimate and our model estimate for the company’s total Medicaid memberships indicate a nearly 2% decline from a year ago.
The consensus estimate for service revenues indicates a 7.2% fall from the year-ago quarter’s $784 million. Also, the Zacks Consensus Estimate for the company’s investment and other income indicates an 11.7% year-over-year decline from $432 million.
Moreover, following the industry trend, CNC’s medical costs are expected to have remained elevated in the third quarter. The Zacks Consensus Estimate for the total health benefits ratio is pegged at 93%, up from 89.2% in the year-ago period, meaning a reduced portion of premiums remaining in hand after paying claims. Our model estimate for total operating expenses indicates more than a 15% increase in the third quarter. These are expected to have affected the bottom line, making an earnings beat uncertain.
Stocks That Warrant a Look
While an earnings beat looks uncertain for Centene, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
Select Medical Holdings Corporation (SEM - Free Report) has an Earnings ESP of +8.58% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Select Medical’s bottom line for the to-be-reported quarter of 18 cents per share has witnessed one upward revision against no downward movement over the past month. The consensus mark for Select Medical’s revenues is pegged at $1.32 billion.
Erasca, Inc. (ERAS - Free Report) has an Earnings ESP of +5.66% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Erasca’s bottom line for the to-be-reported quarter remained stable over the past week. Erasca’s earnings beat estimates in three of the past four quarters and met once, with an average surprise of 13%.
Humana Inc. (HUM - Free Report) has an Earnings ESP of +4.29% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Humana’s bottom line for the to-be-reported quarter is pegged at $2.91 per share, which remained stable over the past week. Humana beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 9.6%.